Detalhe da pesquisa
1.
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
N Engl J Med
; 388(3): 228-239, 2023 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36652354
2.
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
J Hepatol
; 80(2): 322-334, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37972659
3.
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.
Invest New Drugs
; 39(4): 1081-1088, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33660194
4.
Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.
Invest New Drugs
; 38(6): 1846, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32894386
5.
Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.
Invest New Drugs
; 38(6): 1836-1845, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32578154
6.
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping.
Invest New Drugs
; 36(4): 536-544, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29188469
7.
MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis.
J Surg Oncol
; 117(8): 1679-1686, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29790169
8.
A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.
Invest New Drugs
; 34(5): 584-95, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27422720
9.
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients.
Clin Cancer Res
; 30(8): 1466-1477, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38329716
10.
A phase I, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib.
Clin Transl Sci
; 16(9): 1713-1724, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37553804
11.
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma.
Cancers (Basel)
; 15(16)2023 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37627061
12.
A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.
Eur J Nucl Med Mol Imaging
; 39(1): 149-59, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21983837
13.
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.
Clin Lung Cancer
; 23(4): 300-310, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35400584
14.
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 28(11): 2237-2247, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35363301
15.
Sphingosine kinase 1 is a relevant molecular target in gastric cancer.
Anticancer Drugs
; 22(3): 245-52, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21360847
16.
Does endovenous laser ablation induce endothelial damage at the saphenofemoral junction?
Dermatol Surg
; 37(10): 1456-63, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21790851
17.
A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.
J Infect Dis
; 201(3): 354-62, 2010 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20039806
18.
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients.
J Thorac Oncol
; 15(1): 80-90, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31622732
19.
Incidence and Management of Olaratumab Infusion-Related Reactions.
J Oncol Pract
; 15(11): e925-e933, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31268811
20.
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer.
Clin Cancer Res
; 25(17): 5202-5211, 2019 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31142504